TrianglePUBLICATIONS · 37708904
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet
- Publication date
- 2023 Oct 7
- First author
- Wainberg ZA
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Wainberg ZA
- type
- Author
- name
- Melisi D
- type
- Author
- name
- Macarulla T
- type
- Author
- name
- Pazo Cid R
- type
- Author
- name
- Chandana SR
- type
- Author
- name
- De La Fouchardière C
- type
- Author
- name
- Dean A
- type
- Author
- name
- Kiss I
- type
- Author
- name
- Lee WJ
- type
- Author
- name
- Goetze TO
- type
- Author
- name
- Van Cutsem E
- type
- Author
- name
- Paulson AS
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Wainberg ZA
- type
- Author
- name
- Melisi D
- type
- Author
- name
- Macarulla T
- type
- Author
- name
- Pazo Cid R
- type
- Author
- name
- Chandana SR
- type
- Author
- name
- De La Fouchardière C
- type
- Author
- name
- Dean A
- type
- Author
- name
- Kiss I
- type
- Author
- name
- Lee WJ
- type
- Author
- name
- Goetze TO
- type
- Author
- name
- Van Cutsem E
- type
- Author
- name
- Paulson AS
- type
- Author
- bibliography ids
- nci-bib-7382b9bbbb80fbe8cf8742a8
- book metadata
- content sha256
- 76b3efe5f624c2bd12a03a59ffc0cb4caa8f3898a7c6d98949b45c3f6b1decd9
- document type
- citation
- dois
- 10.1016/S0140-6736(23)01366-1
- electronic publication date
- display
- 2023 Sep 11
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37708904
- immutable id
- pubmed:37708904@76b3efe5f624c2bd12a03a59ffc0cb4caa8f3898a7c6d98949b45c3f6b1decd9
- journal
- abbreviation
- Lancet
- issn electronic
- 1474-547X
- issn print
- 0140-6736
- issue
- 10409
- name
- Lancet (London, England)
- nlm unique id
- 2985213R
- pages
- 1272-1281
- volume
- 402
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37708904
- provenance
- batch id
- 5329a5d0877ee70ecd11
- provider
- NCBI PubMed ESummary
- record sha256
- 7b2846787c895406641622e3e43892452c5125127ed0198003f5bbf9cd6a5665
- response sha256
- bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
- retrieved at
- 2026-09-09T23:48:15.763286+00:00
- publication date
- display
- 2023 Oct 7
- precision
- day
- year
- 2023
- publication types
- Randomized Controlled Trial
- Clinical Trial, Phase III
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Preserved source evidence · Not medical advice